Hassan Baig in Jacksonville, Florida

Medical School: Sorry, his university is not listed
Graduation Year: 2012
The Primary Medical Specialty for Hassan Baig is listed as: Pulmonary Disease
Approximate Years of Experience: 12
PAC (PECOS ID)#: 2769753128
NPI #: 1134547250
NPI Created On: 04/05/2014
NPI Last Updated Listed as: 09/02/2020
Primary Taxonomy Code: 207RP1001X
License Number:
ME131358
Listed Gender: Male

Forms of insurance accepted by include, but are not limited to:

• Blue Cross Blue Shield
• Medicare

They are listed as accepting new patients.

Services and Procedures include:

1. Measurement and graphic recording of total and timed exhaled air capacity
2. Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration
3. Multiple measurements and graphic recordings of the amount and speed of breathed air, before and following medication administration
4. Test for exercise-induced lung stress
5. Respiratory inhaled pressure or nonpressure treatment to relieve airway obstruction or for sputum specimen
6. Inhaled pneumonia treatment
7. Determination of lung volumes using plethysmography
8. Measurement of lung diffusing capacity
9. Inhalation of medications with allergic reaction analysis
10. New patient office or other outpatient visit, typically 30 minutes
11. New patient office or other outpatient visit, typically 45 minutes
12. New patient office or other outpatient visit, typically 60 minutes
13. Established patient office or other outpatient visit, typically 5 minutes
14. Established patient office or other outpatient visit, typically 15 minutes
15. Established patient office or other outpatient, visit typically 25 minutes
16. Established patient office or other outpatient, visit typically 40 minutes
17. Subsequent hospital inpatient care, typically 25 minutes per day
18. Subsequent hospital inpatient care, typically 35 minutes per day
19. Critical care delivery critically ill or injured patient, first 30-74 minutes
20. Pentamidine isethionate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 300 mg